Study analysis · The lancet. Diabetes & endocrinology · 2025
Gastric bypass beats sleeve gastrectomy for diabetes remission—but at a price: one in four patients develop low blood sugar after eating.
For people with obesity and type 2 diabetes, gastric bypass leads to diabetes remission in 50% of patients after 5 years versus 20% for sleeve gastrectomy, but 28% of bypass patients experience low blood sugar after meals compared to only 2% for sleeve.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study is like a race where people were randomly chosen to get one of two surgeries. Because they were randomly picked, we can be pretty sure that the differences in results are because of the surgery, not other reasons. But since it was done in just one hospital, we can't be sure the same thing would happen everywhere.
What’s the bottom line?
This study compared two common weight loss surgeries (gastric bypass and sleeve gastrectomy) in people with obesity and type 2 diabetes. They followed patients for 5 years.
How strong is this study?
The study was designed very well: they used a computer to decide who got which surgery, and for the first year, nobody knew who had which one. That makes the results more trustworthy. But after a year, everyone found out, which might have changed some behavior, and the study only happened in one place, so it's not perfect.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
86 / 100
- Randomization+20/20
- Blinding+15/15
- Control group+15/15
- Sample size (n=109)+8.4/20
- Follow-up+10/10
100 / 100
77 / 100
- P-valuesno p-values reported
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registration+15/15
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 569 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
This design can establish causation. Open-label follow-up after 1 year may introduce performance and detection bias; secondary analysis of a trial; single-centre design limits generalizability.
No Conflicts
No conflicts of interest identified
No conflicts identified
Funders
No conflicts of interest declared; funding from a public hospital trust.
Key takeaways
- 01
More people had their diabetes go into remission with gastric bypass (50% vs 20%).
- 02
People lost more weight with gastric bypass (22% vs 17%).
- 03
But more people had low blood sugar after gastric bypass (28% vs 2%).
- 04
Sleeve gastrectomy caused more acid reflux (51% more).
- 05
Yes, the differences are meaningful for choosing surgery.
- 06
Gastric bypass is better for diabetes control and weight loss, but has a higher risk of low blood sugar.
Surprising findings
- 28% of gastric bypass patients had symptomatic low blood sugar after eating, versus only 2% for sleeve gastrectomy.Most people think of hypoglycemia as a rare complication, but this trial shows it's common after gastric bypass.
- The risk difference for pathological acid reflux after sleeve gastrectomy was 51.1% compared to gastric bypass.This is a huge difference that many patients and even some clinicians may underestimate.
Practical takeaways
Patients with type 2 diabetes and obesity considering bariatric surgery should discuss the higher likelihood of diabetes remission with gastric bypass versus the increased risk of hypoglycemia.
This is a single-centre trial with open-label follow-up after 1 year; full text not available for verification.
low confidencePatients undergoing sleeve gastrectomy should be monitored for pathological acid reflux and may need long-term acid suppression therapy.
Not specified if routine screening was recommended; study only reported prevalence at 5 years.
low confidenceWhy this study matters
Diabetes Remission Showdown
At 5 years, 50% of gastric bypass patients had HbA1c ≤6.0% versus 20% for sleeve gastrectomy (risk difference 29.5%). This means gastric bypass is more effective for long-term diabetes control.
Many people assume both surgeries work equally well for diabetes, but this study shows a clear advantage for gastric bypass.
Weight Loss: Gastric Bypass Takes the Lead
Gastric bypass led to a mean total body weight loss of 22.2% versus 17.2% for sleeve gastrectomy (difference 5.0%). That's roughly 10-15 extra pounds for an average patient.
Weight loss is a primary reason for surgery, and this difference could influence patient decisions.
The Hypoglycemia Trade-Off
Symptomatic postprandial hypoglycemia occurred in 28% of gastric bypass patients vs 2% of sleeve patients. This side effect can cause dizziness, confusion, and requires dietary adjustments.
Patients often don't consider this long-term side effect, which can significantly impact quality of life.
Acid Reflux After Sleeve Gastrectomy
Pathological acid reflux was far more common after sleeve gastrectomy (risk difference 51.1% compared to bypass). Erosive esophagitis and Barrett's esophagus rates were similar between groups.
Reflux is a known issue after sleeve, but this study quantifies how much more likely it is compared to bypass.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
This study compared two common weight loss surgeries (gastric bypass and sleeve gastrectomy) in people with obesity and type 2 diabetes. They followed patients for 5 years.
Research results
More people had their diabetes go into remission with gastric bypass (50% vs 20%). People lost more weight with gastric bypass (22% vs 17%). But more people had low blood sugar after gastric bypass (28% vs 2%). Sleeve gastrectomy caused more acid reflux (51% more).
What this means - more context
Yes, the differences are meaningful for choosing surgery. Gastric bypass is better for diabetes control and weight loss, but has a higher risk of low blood sugar.
To compare the effects of gastric bypass and sleeve gastrectomy on type 2 diabetes remission, weight loss, and cardiovascular risk factors 5 years after surgery.
At 5 years, gastric bypass led to higher type 2 diabetes remission (50% vs 20% for HbA1c ≤6.0%), greater weight loss (22.2% vs 17.2%), and lower LDL cholesterol, but more symptomatic postprandial hypoglycemia (28% vs 2%). Sleeve gastrectomy resulted in more pathological acid reflux (risk difference 51.1%).
Methods Used
Secondary analysis of a single-centre, triple-blind, randomized controlled trial at a public tertiary obesity centre in Norway. 109 adults with type 2 diabetes and obesity were randomly assigned to laparoscopic gastric bypass or sleeve gastrectomy. 93 (85%) completed 5-year follow-up.
Main Finding
Gastric bypass was superior to sleeve gastrectomy for long-term type 2 diabetes remission, weight loss, and LDL cholesterol reduction, at the expense of a higher frequency of symptomatic postprandial hypoglycemia.
Confidence Level
High - based on a randomized controlled trial with blinding and 5-year follow-up, but full text not available for verification of methodology details.
Study Flags
Red Flags
- •Full text not available - methodology details cannot be verified
- •Single-centre design may limit generalizability
- •Open-label after 1 year may introduce bias
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Surprising Findings
28% of gastric bypass patients had symptomatic low blood sugar after eating, versus only 2% for sleeve gastrectomy.
Most people think of hypoglycemia as a rare complication, but this trial shows it's common after gastric bypass.
Practical Takeaways
Patients with type 2 diabetes and obesity considering bariatric surgery should discuss the higher likelihood of diabetes remission with gastric bypass versus the increased risk of hypoglycemia.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 569 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Human RCT
Subject
Moderate probability
on the GRADE evidence scale
This study is like a race where people were randomly chosen to get one of two surgeries. Because they were randomly picked, we can be pretty sure that the differences in results are because of the surgery, not other reasons. But since it was done in just one hospital, we can't be sure the same thing would happen everywhere.
The study has a COI section but no disclosure was found. A small penalty has been applied.
Strengths
- Randomized design with computer-generated allocation
- Triple-blind for first year (participants, personnel, outcome assessor)
- Good follow-up rate (85%) at 5 years
Weaknesses
- Full methodology not available - based on abstract only
- Open-label follow-up after 1 year may introduce bias
- Secondary analysis (not primary endpoint)
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
This study compared two common weight loss surgeries (gastric bypass and sleeve gastrectomy) in people with obesity and type 2 diabetes. They followed patients for 5 years.
Research results
More people had their diabetes go into remission with gastric bypass (50% vs 20%). People lost more weight with gastric bypass (22% vs 17%). But more people had low blood sugar after gastric bypass (28% vs 2%). Sleeve gastrectomy caused more acid reflux (51% more).
What this means - more context
Yes, the differences are meaningful for choosing surgery. Gastric bypass is better for diabetes control and weight loss, but has a higher risk of low blood sugar.
To compare the effects of gastric bypass and sleeve gastrectomy on type 2 diabetes remission, weight loss, and cardiovascular risk factors 5 years after surgery.
At 5 years, gastric bypass led to higher type 2 diabetes remission (50% vs 20% for HbA1c ≤6.0%), greater weight loss (22.2% vs 17.2%), and lower LDL cholesterol, but more symptomatic postprandial hypoglycemia (28% vs 2%). Sleeve gastrectomy resulted in more pathological acid reflux (risk difference 51.1%).
Methods Used
Secondary analysis of a single-centre, triple-blind, randomized controlled trial at a public tertiary obesity centre in Norway. 109 adults with type 2 diabetes and obesity were randomly assigned to laparoscopic gastric bypass or sleeve gastrectomy. 93 (85%) completed 5-year follow-up.
Main Finding
Gastric bypass was superior to sleeve gastrectomy for long-term type 2 diabetes remission, weight loss, and LDL cholesterol reduction, at the expense of a higher frequency of symptomatic postprandial hypoglycemia.
Confidence Level
High - based on a randomized controlled trial with blinding and 5-year follow-up, but full text not available for verification of methodology details.
Study Flags
Red Flags
- •Full text not available - methodology details cannot be verified
- •Single-centre design may limit generalizability
- •Open-label after 1 year may introduce bias
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Surprising Findings
28% of gastric bypass patients had symptomatic low blood sugar after eating, versus only 2% for sleeve gastrectomy.
Most people think of hypoglycemia as a rare complication, but this trial shows it's common after gastric bypass.
Practical Takeaways
Patients with type 2 diabetes and obesity considering bariatric surgery should discuss the higher likelihood of diabetes remission with gastric bypass versus the increased risk of hypoglycemia.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 569 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Human RCT
Subject
Moderate probability
on the GRADE evidence scale
This study is like a race where people were randomly chosen to get one of two surgeries. Because they were randomly picked, we can be pretty sure that the differences in results are because of the surgery, not other reasons. But since it was done in just one hospital, we can't be sure the same thing would happen everywhere.
The study has a COI section but no disclosure was found. A small penalty has been applied.
Strengths
- Randomized design with computer-generated allocation
- Triple-blind for first year (participants, personnel, outcome assessor)
- Good follow-up rate (85%) at 5 years
Weaknesses
- Full methodology not available - based on abstract only
- Open-label follow-up after 1 year may introduce bias
- Secondary analysis (not primary endpoint)
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
The study was designed very well: they used a computer to decide who got which surgery, and for the first year, nobody knew who had which one. That makes the results more trustworthy. But after a year, everyone found out, which might have changed some behavior, and the study only happened in one place, so it's not perfect.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
86 / 100
- Randomization+20/20
- Blinding+15/15
- Control group+15/15
- Sample size (n=109)+8.4/20
- Follow-up+10/10
100 / 100
77 / 100
- P-valuesno p-values reported
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registration+15/15
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 569 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
This design can establish causation. Open-label follow-up after 1 year may introduce performance and detection bias; secondary analysis of a trial; single-centre design limits generalizability.
No Conflicts
No conflicts of interest identified
No conflicts identified
Funders
No conflicts of interest declared; funding from a public hospital trust.